liking schizophrenia

Augmentation Strategies for Depression | Psychiatric Times

Reading now: 488
wingofmadness.com

Several years ago, I was approached by a pharmaceutical representative who wanted to tell me about a “new” agent, brexpiprazole.

Sure, I was familiar with it having learned about it in training—the serotonin 1A and dopamine D2 receptors partial agonist and serotonin 2A and noradrenaline alpha receptors antagonist that was FDA-approved for schizophrenia and as adjunctive therapy to antidepressant for major depressive disorder (MDD).1 But there is no way I would use it; after all it was likely just another “pharma” push of a drug that would not work, right?At least in academia we have been groomed to see such advancements as an advertisement or a marketing scheme, and it is taboo to engage in discussions, let alone prescribe, a marketed drug.

Read more on wingofmadness.com
The website mental.guide is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles

DMCA